Alnylam Pharmaceuticals, Inc.
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V
Last updated:
Abstract:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
Status:
Application
Type:
Utility
Filling date:
23 Feb 2021
Issue date:
24 Jun 2021